Nabis Launches Online Cannabis Marketplace Platform in New York, Streamlining Growing Supply Chain
The Leading Wholesale Platform Empowers Producers and Retailers Under One Platform, Leveraging Powerful Automation, Compliance, and Fulfillment Tools
NEW YORK, June 24, 2025--(BUSINESS WIRE)--Nabis, the world's leading licensed cannabis wholesale platform, is launching its digital Marketplace in New York. Along with Nabis' robust fulfillment services, the Marketplace brings the company's full suite of distribution, financing, and analytics technology to one of the country's fastest-growing cannabis markets.
New York's cannabis market is rapidly evolving, with adult-use quickly approaching $1.5 billion in cumulative sales since 2022. In May of 2025 alone, the market generated $114.6 million in sales—a 100.4% year-over-year increase. As the number of licensed retailers climbs and consumer demand accelerates, operators across the state are racing to keep up. Nabis' Marketplace arrives at a pivotal moment, offering a scalable supply chain solution designed to meet that rising demand, reduce friction in B2B transactions and enable businesses of all sizes to grow sustainably.
"Tech infrastructure has the power to amplify growth and access across operators of all sizes," said Vince C. Ning, Co-Founder and CEO of Nabis. "With e-commerce services such as sales-enablement, marketing, financing, and logistics that are purpose-built for cannabis, we're providing brands and retailers tools to thrive in a fragmented environment as we expand across New York."
The Marketplace intentionally meets the distinct needs of both small brands and larger multi-state operators building their businesses in an evolving regulatory landscape. While small brands benefit from increased visibility and streamlined access to retailers, larger brands gain centralized tools to manage diverse SKUs, fulfill orders across multiple retail accounts, and automate their B2B transactions at scale. The platform is launching with nearly 40 brands including local operators like Hepworth and Central Processors NY—which houses High Peaks, Generic AF and ZONK!—and multi-state operators like Jetty Extracts and Smokiez, among others.
On the other side of the supply chain, retailers can seamlessly browse across multiple brand catalogs and view real-time inventory, track deliveries, and manage invoices all in one place. Additionally, integrations between Nabis and industry-leading point-of-sale systems will also allow retailers to gain access to automated order suggestions, real-time inventory insights, and custom pricing tools—bringing smarter, data-informed decision-making directly into their day-to-day workflows and reducing manual processes.
In addition to streamlining fulfillment and order placement, this integration will support brands keeping products in stock at high-performing retail locations. By monitoring sell-through data and pre-positioning inventory for delivery, brands are able to meet demand more efficiently while reducing overhead for retailers.
By consolidating otherwise siloed logistics and bundling fulfillment, Nabis enables faster, more efficient distribution. This expansion further deepens Nabis' infrastructure investment in New York, complementing two operational distribution hubs, in the Bronx and Rochester, as it builds a smarter, more sustainable cannabis industry.
"We're proud to partner with both emerging and established operators to bring a new level of operational efficiency to New York's cannabis economy, particularly as the state's Biotrack seed-to-sale system comes online," said Ning. "This launch is about more than technology—it's about creating simple-to-use infrastructure in a regulated market so that it works for everyone."
To learn more about how to join the Nabis Marketplace in New York, visit nabis.com.
About Nabis
Nabis is the #1 licensed cannabis wholesale platform, servicing over 400 brands. Founded in 2018 by serial tech entrepreneurs Vince C. Ning and Jun S. Lee, Nabis is on a mission to build the most powerful licensed cannabis wholesale platform with a multi-channel fulfillment network that simplifies cannabis commerce for brands and retailers anywhere in the world. Nabis is the largest licensed wholesaler in the industry, having supported numerous exclusive brands and retailers transact over $1B worth of cannabis products in major states across the nation. As Nabis continues its national expansion, the privately-held multistate operator utilizes its experience in the world's largest legal cannabis markets and offers its partners an online wholesale marketplace with best-in-class fulfillment, payment processing, financing, data analytics, and sales and marketing services to enable more brands and retailers to innovate, launch, and scale strategically. Ning and Lee's work earned Nabis a spot on Inc. 5000's list of Fastest Growing Private Companies in America in 2023, Fast Company's list of the 50 Most Innovative Companies in America in 2024, and on Deloitte's Fast 500 List of Technology leaders in 2024. Learn more: nabis.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250624314738/en/
Contacts
Media Contact: Molly SposatoGrasslands: A Journalism-Minded Agencymolly@mygrasslands.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2). 'We are highly encouraged by the FDA's positive feedback on our proposed development plan for this important program. We believe CUE-401, with its first-in-class mechanism exploiting the combined activities of TGF-β and IL-2 is a potentially disruptive approach differentiated from other Treg-directed therapies, and has the potential to provide durable, long-lasting immune rebalance and tolerance addressing multiple, significant disease indications,' said Daniel Passeri, chief executive officer of Cue Biopharma. Dr. Dan Baker, chief development officer of Cue Biopharma commented, 'CUE-401's mechanistic design extends beyond nTreg proliferation by transforming effector/autoreactive responses to an anti-inflammatory and/or suppressive response, with the prospects of establishing tolerance. The combination of interleukin 2 (IL-2) and transforming growth factor beta (TGF-ß) is considered the 'master switch' for conversion of activated T effector cells into T cells with a regulatory phenotype.' About CUE-401CUE-401 is a preclinical, bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) through the co-activity of modified variants of transforming growth factor beta (TGF-β) and interleukin 2 (IL-2) with therapeutic potential across a range of T-cell mediated autoimmune and inflammatory diseases. CUE-401 has been engineered to harness the Treg induction capacity of TGF-β combined with IL-2 signaling to provide what Cue Biopharma believes to be superior quality and stability of Tregs. The design and specifications of CUE-401 have been guided by leading scientific publications demonstrating that both IL-2 and TGF-β are required for stable and efficient production of active and durable Tregs. CUE-401 is designed to overcome multiple hurdles required to exploit the therapeutic potential of a master switch with a first-in-class, bispecific molecule integrating a masked TGF-ß, with our clinically validated, attenuated IL-2 with an antibody Fc fragment. This novel design provides for 'conditional binding' and avoids off target activity, simplifies manufacturing and has highly differentiated findings in multiple pre-clinical models. In these models, CUE-401 behaves as a master switch to convert autoreactive effector T cells (inflammatory cells) into stable, induced T-regulatory cells (iTregs). These findings suggest that CUE-401 acts by establishing a 'tolerance positive feedback loop' that not only increases nonspecific Treg populations, but critically, reduces and converts specific autoreactive T cells into transdifferentiated iTregs that are specific for the disease-causing autoantigens. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit and follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's expectations regarding the planned IND filing for CUE-401; the Company' expectations regarding the potential characteristics and benefit of CUE-401; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'would,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'project,' 'estimate,' 'anticipate,' 'strategy,' 'future,' 'likely' or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's pipeline of product candidates and platforms, and its strategies, prospects, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to successfully advance is development plan for CUE-401; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ('FDA') or other governmental approvals for its product candidates, including FDA clearance of any future IND submission for CUE-401, and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the near term; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Media ContactJonathan PappasLifeSci Communicationsjpappas@
Yahoo
an hour ago
- Yahoo
FromZero.ai Launches Favicon Gallery, Targeting Guinness World Record for Largest Digital Mosaic
Interactive online mosaic invites users worldwide to permanently claim custom favicon tiles as part of a record-setting digital artwork San Francisco, California, June 24, 2025 (GLOBE NEWSWIRE) -- today announced the launch of Favicon Gallery, a large-scale digital mosaic project inviting users to permanently claim custom favicon tiles on an interactive online canvas. The project is aiming to set a Guinness World Record for the largest digital mosaic of favicons built in the shortest time. Favicon Gallery by — Guinness World Record mosaic in Gallery features a 100,000-tile digital canvas where each tile can be claimed for $99.99 USD. Participants upload their own favicon image, link, and title, contributing to a growing visual record of internet culture. The project is designed to encourage creativity, community engagement, and bold participation in digital spaces. Created as a public 'from zero' experiment without initial funding or code, Favicon Gallery reflects a philosophy of action over hesitation, demonstrating how ideas can be built openly and collaboratively online. 'Favicon Gallery is a live demonstration of how taking action can drive creativity and progress in the digital world,' said creator Sylvester M. 'We hope this inspires others to contribute, take creative risks, and become part of an evolving piece of internet history.' As the mosaic fills, will formally apply to Guinness World Records for recognition as the world's largest digital favicon mosaic created in the shortest timeframe. The long-term vision is for Favicon Gallery to generate funding that will support future digital ventures and creative innovation through open, community-driven projects. Favicon Gallery transforms the small, often-overlooked favicon, the tiny icon seen in browser tabs, into a platform for digital expression. Each tile in the mosaic represents permanent online real estate, owned and curated by individual participants. The project showcases contributions from creators, entrepreneurs, brands, and communities around the world. Built publicly from day one, Favicon Gallery emphasizes transparency and accessibility. Its development is openly documented on social channels and the project site. Current milestones include reaching 10,000–20,000 claimed tiles as the team builds momentum toward the Guinness World Record Favicon GalleryFavicon Gallery is an interactive digital mosaic created by The platform invites users worldwide to claim custom favicon tiles, contributing to a global artwork that celebrates creativity, internet culture, and bold claim a tile or learn more, visit: Sylvester M. Creator, contact@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
S&P 500 Gains and Losses Today: Coinbase Shares Soar; Oil and Defense Stocks Drop
The S&P 500 added 1.1% on Tuesday, June 24, 2025, as optimism spread about a possible de-escalation in the conflict between Israel and Iran. Coinbase shares surged, extending their solid rally as Benchmark analysts boosted their price target on the cryptocurrency exchange operator's stock. The potential for an alleviation of geopolitical tensions contributed to a drop in oil prices, pressuring oil and gas stocks, while aerospace and defense stocks also lost U.S. equities indexes gained ground on Tuesday after President Donald Trump announced a ceasefire agreement between Iran and Israel, raising hopes for a more sustained drawdown in hostilities. Investors also kept an eye on Congressional testimony by Federal Reserve Chair Jerome Powell. Powell indicated that the central bank intends to maintain interest rates at their current levels until there is more clarity on tariff policy and its potential economic impact, despite the White House's calls for immediate rate cuts. The S&P 500 gained 1.1%, closing just beneath its record-high level set in February. The Dow was up 1.2%, while the Nasdaq jumped 1.4%. Shares of Coinbase Global (COIN), operator of the largest cryptocurrency exchange in the U.S., skyrocketed 12.1% on Tuesday to secure the S&P 500's top performance. Analysts at the research firm Benchmark lifted their price target on Coinbase stock, pointing to favorable legislative and regulatory developments and the company's initiatives to capitalize on them. Secretary of Health and Human Services Robert F. Kennedy Jr. announced that the department would launch a massive advertising campaign to encourage the use of wearable health devices. Kennedy specifically mentioned the benefits of glucose monitors for patients managing diabetes. Shares of glucose monitor manufacturer Dexcom (DXCM) surged 9.7%. Uber Technologies (UBER) shares jumped 7.5% as the ridesharing company debuted its robotaxi service in Atlanta. Uber's partnership with Waymo, the autonomous vehicle company owned by Google parent Alphabet (GOOGL), initially offers service in 65 square miles of Atlanta, around half the city's footprint. Carnival Corporation (CCL) posted better-than-expected sales and profits for its fiscal first quarter, and the cruise operator's shares sailed 6.9% higher. The company also boosted its full-year profit outlook, pointing to increases in passengers carried and passenger cruise days as well as declining costs. Shares of competitors Norwegian Cruise Line Holdings (NCLH) and Royal Caribbean Group (RCL) also advanced. AutoZone (AZO) shares dropped 3.6%, losing the most of any S&P 500 stock on Tuesday, following reports that a senior vice president at the auto parts retailer had sold a stake in the company worth more than $2.5 million. Investors often view large sales by company insiders as a negative signal for a stock. Crude oil futures tumbled as optimism around de-escalation in the Middle East helped alleviate potential supply concerns. Shares of energy company Occidental Petroleum (OXY) fell 3.3%, while Exxon Mobil shares (XOM) were down 3%. The potential for calming geopolitical tensions also pressured defense stocks. Northrop Grumman (NOC) shares dropped 3.2%, while shares of aerospace and defense peers RTX Corp. (RTX) and Lockheed Martin (LMT) also traded lower. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
